Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus
Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus
复制标题
DOI：
10.1038/sj.cgt.7700241
复制
发表时间：
2000-11-01
影响因子：
6.4
通讯作者：
Kratzke, RA
中科院分区：
文献类型：
--
作者：
Frizelle, SP;Rubins, JB;Kratzke, RA
几乎在所有间皮瘤肿瘤和细胞系中都观察到p16（INK4a）基因产物的缺失，而野生型pRB的表达则保持不变。我们已经研究了p16（INK4a）基因产物在已建立的人类间皮瘤异种移植小鼠中重新表达的潜在治疗作用。使用Adp16治疗异种间皮瘤的实验表明，采用基于p16（INK4a）的基因治疗后，间皮瘤存活时间延长，并有可能治愈。这些结果表明p16（INK4a）基因转移可能在间皮瘤的治疗中发挥治疗作用。
The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.